The AML1/CBFA2/RUNX1 gene is the target of many recurrent translocations seen in different leukemia subtypes. The t(12;21)(p13;q22) is the most frequent translocation observed in childhood B acute lymphoblastic leukemia (ALL), occurring in 20% to 25% of cases. In adult ALL this rearrangement is scarce. Another route of AML1 deregulation could be point mutations in the runt domain. We now report on AML1 amplification in two cases of childhood ALL, found in a series of 107 consecutive children with B-lineage ALL analyzed by fluorescence in situ hybridization (FISH). A parallel analysis of 42 adult B-ALL failed to detect any AML1 rearrangement by FISH. The two patients with AML1 amplification were further analyzed using molecular techniques. SSCP analysis did not detect any mutation. Furthermore, direct sequencing of the cDNA did not reveal any mutation. In conclusion, AML1 amplification seems to be observed only in childhood ALL and is not associated with AML1 gene mutation. Other mechanisms, such as gene dosage effects could be hypothesized.
Introduction
The AML1/CBFA2/RUNX1 gene, located in the chromosomal band 21q22, belongs to the runt domain family that encodes the ␣ subunit of heterodimeric transcription factor PEBP2/CBF. The runt domain is an evolutionarily conserved protein motif that consists of 128 amino acids and is responsible for both DNA-binding and heterodimerization with the non DNAbinding regulatory ␤ subunit, CBF␤ (core binding factor). CBF␤ increases the DNA binding affinity of AML1. AML1 is normally expressed in all hematopoietic lineages and acts to regulate the expression of various genes such as the granulocyte colony stimulating factor, interleukin 3, T cell receptor ␤ and myeloperoxidase (MPO) genes. Furthermore, mice lacking either AML1 or CBF␤ are defective in definitive hematopoiesis of all lineages. The AML1 gene is the target of many common translocations seen in different leukemia subtypes, leading to the formation of fusion genes: AML1/ETO in t(8;21); AML1/EVI1, AML/MDS1 and AML/EAP in t(3;21) and ETV6/AML1 in t (12;21) . The translocation t(12;21)(p13;q22) is the most frequent molecular genetic aberration in childhood B acute lymphoblastic leukemia, occurring in 20% to 25% of cases. In adults, this translocation has been rarely reported.
cations in leukemogenesis, the versatile roles of AML1 in hematopoiesis led to the hypothesis that other mechanisms such as mutations might be involved in some cases of leukemias. Preudhomme et al 4 Genomic amplification is a frequent genetic abnormality in solid tumors and many oncogenes are activated in this way. Cytogenetically, two forms of amplified genes have been described, either as extended chromosomes named homogeneously staining regions (HSR) or as extra chromosomal elements, called double minute (dmin) chromosomes. However, in cases with complex karyotypes, gene amplification may be missed by conventional cytogenetics. In hematologic malignancies, gene amplification is uncommon. Few large series have focused on this point, and the estimated incidence of cytogenetically detectable gene amplification in AML is about 1%. 10 C-myc appears to be the most frequently amplified gene in AML, 11 whereas cases showing amplification of other genes such as MLL have been rarely reported. 12 Because the t(12;21) is not detectable by conventional cytogenetics, we use FISH with ETV6/AML1 probes which enables the detection of the translocation in each case of ALL. Recently, we found two cases of amplification of the AML1 gene in 'old' children, 17 and 19 years old. This led us to test the probes in all our adult B ALL for whom frozen cells were available. For these two cases, we also performed molecular analysis of the runt domain of AML1 to check for mutations. The aim of our study was to determine the incidence of AML1 amplification in childhood and adult ALL, and furthermore, to elucidate the mechanisms underlying the role of AML1 in leukemogenesis.
Materials and methods

Materials
Bone marrow samples were obtained for 107 children (age р20 years), with a median age of 5 years (range 0-20) at the time of diagnosis and 42 adults (age Ͼ 20 years) with a median age of 49 years (range 21-78). All 149 patients presented a pre-B ALL. None of the 149 patients had Down's syndrome.
Methods
Standard chromosomes RHG banding analysis was performed on mitotic bone marrow cells after short-term culture for all the cases. FISH analysis was performed on frozen cytogenetic preparations or on viable leukemic cells frozen in DMSO. We used SpectrumGreen and SpectrumOrange-conjugated dualcolor DNA probes specific for the ETV6 and AML1 genes (Vysis, Voisins-le-Bretonneux, France). Hybridization and washes were performed according to the manufacturer's instructions. We also used a chromosome 21 painting probe (Vysis) to identify two der (21) .
Detection of AML1 gene runt domain mutations was performed firstly on DNA extracted from bone marrow by singlestrand conformation polymorphism (SSCP) analysis as previously described by Preudhomme et al. 4 Secondly, all the coding sequence of the AML1 cDNA was sequenced. Briefly, total RNA was extracted from frozen aliquots of 10 7 bone marrow cells with Trizol reagent (Life Technologies, Paisley, UK) according to the manufacturer's instruction. RNA pellets were resuspended in 10 l of RNAse-free water and quantity was estimated by ultraviolet spectrofluorometry. cDNA was synthesized from 1 g of total RNA in a 20 l reaction mixture as previously described. 15 Three PCR amplifications were performed in parallel: each containing 2 l of cDNA (corresponding to 100 ng of total RNA), 1× TaqGold reaction buffer (Applied Biosystem, Foster City, CA, USA), 1.5 mm MgCl 2 , 250 m each dATP, dCTP, dGTP, dTTP (Pharmacia, Uppsala, Sweden), 0.5 U of AmpliTaq Gold polymerase (Applied Biosystem) and 50 pmol of each primer (see Table 1 ). Thermocycling conditions used were 12 min at 94°C followed by 35 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, extention at 72°C for 1 min and a final extension step of 5 min at 72°C. After purification on QIAquick PCR purification columns (Qiagen, Hilden, Germany), 577 bp, 465 bp and 426 bp PCR fragments were sequenced following the ABI protocol for Taq-Dye Terminator Sequencing on an automated ABI377 sequencer. Sequences were analyzed with the Sequence Analysis software V3.3 and the Sequence Navigator software V1.0.1 (Applied Biosystem). Sequencing was performed on both strands.
Results
In the adult group, conventional karyotype was attempted for all of them. To complete the karyotypic diagnosis, we system- atically used a BCR/ABL probe (Vysis), and a MLL probe (Vysis). The ETV6/AML1 probe was not tested routinely, and was especially used in this study in order to detect AML1 gene amplification. Forty-two bone marrow samples from adults (25 males and 17 females) with ALL were analyzed. Karyotype was normal in eight patients, whereas 13 patients presented t(9;22), four patients presented hyperdiploidy, and one patient was hypodiploid. None of these 42 adult ALL patients displayed ETV6/AML1 fusion. In two cases, we found three and four copies of AML1, but in both cases, cytogenetics revealed a near-triploid and near-tetraploid, respectively. In one case with t(9;22), we observed only one signal with the ETV6 probe in 38% of cells, probably reflecting a microdeletion on the short arm of chromosome 12.
The systematic use of ETV6/AML1 probes on childhood pre-B ALL enabled the identification of 12/107 (11.2%) gene fusion, in 10 girls and two boys. Thirty-one children displayed hyperdiploidy, and the number of AML1 signals by FISH was always in agreement with the number of chromosomes 21 on the karyotype. Two patients presented amplification of the AML1 gene.
The first patient was a 17-year-old boy admitted to hospital for a bilateral lung infection. A peripheral blood count showed a leukocyte count of 1000/l and the differential count indicated 82% blast cells, hemoglobin was 3.6 g/dl and platelet count of 51 000/l. By flow cytometry, blasts were found to be positive for CD19, CD79a, CD22 and c, whereas sIg were negative. Bone marrow aspirate confirmed the diagnosis of ALL. The patient was treated by chemotherapy according to the FRALLE protocol. He remains in continuous remission with maintenance chemotherapy 10 months after diagnosis. The karyotype was: 46,XY,add(1)(q25),add(21)(q21) [6] /46, XY [14] . FISH analysis did not reveal ETV6/AML1 fusion, but an AML1 gene amplification with eight copies on interphase cells. Metaphase cell analysis showed that one signal was on a normal chromosome 21, whereas the seven other signals were all on a marker chromosome (Figure 1 ). Further analyses with a chromosome 21 painting probe revealed that this marker was a derivative chromosome 21.
The second patient was a 19-year-old girl admitted to hospital for tonsil infection. The peripheral blood count showed a leukocyte count of 10 100/l with 72% of blast cells, hemoglobin was 5.1 g/dl and the platelet count 6000/l. By flow cytometry, blast cells were found to be positive for CD19, CD79a, CD22, CD10 and negative for c and sIg. Bone marrow aspirates confirmed the diagnosis of ALL. The patient received chemotherapy according to the FRALLE 2000 protocol and remains in continuous remission with maintenance chemotherapy 12 months after diagnosis. Cytogenetic analysis revealed an abnormal karyotype : 46,XX,del(7)(p14p21),−21, +mar [10] /46,XY [2] . FISH experiments using the ETV6/AML1 probe did not show gene fusion, but an AML1 amplification, with six to eight copies on interphase cells. Metaphase cells analysis revealed that one AML1 signal was localized on a normal chromosome 21, whereas five to seven other signals were on the marker chromosome (Figure 1 ). Here again, metaphase FISH experiments using a chromosome 21 painting probe showed that the marker was a derivative chromosome 21 .
The molecular analysis of the two cases with AML1 amplification was performed using the SSCP analysis and direct sequencing of the AML1 cDNA. In both cases, we did not find any mutation, particularly in exons 3, 4 and 5, which correspond to the runt domain and are known to be mutated in some types of myeloid leukemias. (21) with AML1 amplification, the red signal is the normal AML1 and the two green signals indicate the two ETV6 alleles. Patient 2: FISH analysis of AML1 amplification with the ETV6/AML1 probes: on the metaphase, the red arrow indicates the der(21) with AML1 amplification, the red signal is the normal AML1 and the green signal indicates the ETV6 allele, the second ETV6 allele being lost. On the interphase nucleus, red signals indicates the six to eight copies of AML1 and the green signal indicates the ETV6 allele.
Discussion
Chromosomal translocations involving the AML1 gene are recurrent genomic alterations observed in both ALL and AML. In ALL, the most frequent translocation is t(12;21)(p13;q22), which fuses ETV6 to AML1. It occurs in about 20% of pediatric ALL and generally predicts a good response to treatment. 13 In this study, our cytogenetic results are in agreement with previous studies, for both children and adults. Kwong et al 3 found only one ETV6/AML1 fusion among 26 (3.3%) adult ALL. This rare fusion was confirmed by Raynaud et al 14 in a study of 118 adult ALL (age Ͼ16 years), who found only one Leukemia (1.1%) ETV6/AML1 fusion in a 19-year-old patient. Among the 42 adults analyzed in our series, no t(12;21) was observed, in agreement with other series.
Recently, Niini et al 8 and Dal Cin et al 7 described AML1 amplification in three and two children, respectively, with ALL aged 12, 5 and 2 years old in Niini's study and 10 and 11 years old in Dal Cin's study. Even more recently, Busson-Le Coniat et al 9 reported three children (15, 6 and 11 years old, respectively) with extra copies of AML1. The clinical presentation was similar to classical t(12;21) ALL. Because our two cases of AML1 amplification occurred in 'old' children, 17 and 19 years old, this led us to screen adult ALL patients for AML1 amplification even if no such case has been described in the literature. In order to accurately determine the amplification level, the ploidy of the specimen has to be known to not confuse extra copies of a gene instead of surnumerary chromosomes. In our series, cytogenetic analysis was performed in all the cases to rule out such pitfalls. The cases presented herein and those reported by Niini, 8 Dal Cin 7 and Busson-Le Coniat 9 show that AML1 amplification is closely related to childhood ALL rather than to adult ALL, even though the 10 children reported are slightly older than usual pediatric patients (median age = 11).
A poor outcome is generally associated with the finding of dmin or HSR as a consequence of dysregulated expression of amplified genes. 16 Our cases are both still in complete remission 10 and 12 months after diagnosis and have displayed a good response to chemotherapy although the followup is short. These amplified cases raise the question of the mechanism of gene amplification, and furthermore, raise the question of the role of this amplification in leukemogenesis. Only one of seven karyotypes was normal, and the abnormalities are not recurrent in ALL. In our patients, BCR/ABL and MLL rearrangements have been ruled out.
The oncogenic mechanisms involved in AML1 amplification are still unknown. A possible hypothesis would be the existence of mutations especially in the runt domain, leading to an inactive form of AML1. Such mutations of the runt domain have been described in myeloid malignancies. A unique mutation has been reported in a child with ALL. These mutated AML1 forms act as dominant-negative proteins leading to leukemogenesis. In our two amplified cases we did not find any mutation at the DNA level. To definitely rule out the theoretical possibility of a point mutation involving only one of the eight AML1 copies (which could have been preferentially overexpressed), we performed sequencing of the cDNA. This analysis failed to detect any mutation. Thus, AML1 deregulation occurred through another mechanism. Usually a heterodimerization is formed between AML1 and CBF␤. The requirement of CBF␤ for AML1 function is strongly supported by the creation of CBF␤ knockout mice. [17] [18] [19] [20] These mice present the same spectrum of abnormalities (mid-gestation lethality, central nervous system hemorrhage, lack of fetal liver hematopoiesis) as AML1 knockout mice. [17] [18] [19] [20] This functional defect has been shown to be intrinsic to hematopoietic stem cells suggesting that AML1/CBF␤ functions as a regulator that controls the formation of the definitive hematopoietic stem cells, or their survival, proliferation and/or differentiation. 21 Our cases are not rearranged or mutated, but we could not exclude other rearrangements not detectectable by our technical approaches. Another hypothesis would be a gene-dosage effect, involving AML1, with so far unknown biological significance. However, other genes might be co-amplified, and be responsible for the oncogenetic effects.
In conclusion, AML1 amplifications are rarely observed and seem to be related to ALL childhood. More observations are needed to (1) define the exact incidence of AML1 amplifications, (2) correlate these amplifications with specific clinical characteristics, and (3) understand the molecular mechanisms involved in leukemogenesis.
